Series B
Seaport Therapeutics Secures $225 Million in Oversubscribed Series B Funding
Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, biotech investment
Purespring Therapeutics Secures £80M ($105M) Series B Funding to Advance IgAN Gene Therapy into Clinical Trials
Purespring Therapeutics, IgAN gene therapy, kidney disease, Series B funding, clinical trials, AAV gene therapy, podocytes, nephrotic syndrome, glomerular kidney disease.
Mendaera Secures $73M Series B Funding to Revolutionize Mainstream Medical Procedures with Robotics and AI
Mendaera, Series B funding, robotics, AI, medical procedures, healthcare technology, Threshold Ventures
Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease
Resolution Therapeutics, Series B funding, macrophage cell therapy, liver disease, regenerative medicine, biopharmaceuticals
Aktis Oncology Secures $175M Series B Funding with Backing from Industry Giants
Aktis Oncology, Series B funding, targeted alpha radiopharmaceuticals, cancer treatment, pharmaceutical industry, investment, Lilly, BMY, MRK.
OrsoBio Secures $67 Million in Funding for Next-Generation Obesity Treatments
OrsoBio, obesity drugs, Eli Lilly, Series B funding, weight loss medicines, metabolic disorders
PreciseDx Secures $20.7 Million in Series B Funding to Enhance AI-Driven Breast Cancer Risk Assessments
PreciseDx, AI-Powered Cancer Risk Assessments, Breast Cancer Diagnostics, Series B Funding, Precision Medicine
Halda Therapeutics Secures $126M in Series B Funding to Advance Next-Gen Oral TACs
Halda Therapeutics, Series B funding, next-gen oral TACs, biotech, clinical trials, prostate cancer
Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market
Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures
Pheon Secures $120 Million in Series B Funding to Revolutionize Treatment for Challenging Cancers with Advanced Antibody-Drug Conjugates
Pheon, Series B funding, $120 million, hard-to-treat cancers, antibody-drug conjugates (ADCs), cancer treatment, biotechnology, healthcare innovation.